HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Cosmetic Talc Lawsuits Halted, $2Bn Trust Created, As Subsidiary Takes Liabilities Into Bankruptcy

Executive Summary

Johnson & Johnson’s newly created subsidiary LTL Management LLC will take all cosmetic talc injury claims against the Johnson’s Baby Powder manufacturer into bankruptcy proceedings. J&J says the move is designed to ensure “equitable” resolution for all parties, while plaintiff’s attorneys have a decidedly different view on the matter.

You may also be interested in...

Henrietta Lacks’ Harvested Cells: Is The Clock Ticking On Unjust Enrichment Claim?

The descendants of Henrietta Lacks, a Black woman whose non-consensually harvested cervical cancer cells became the famous HeLa cell line, are suing Thermo Fisher Scientific. The family argue that Thermo Fisher’s ongoing profits from the various HeLa cell lines it commercializes and sells constitute unjust enrichment.

J&J Adds $6.9bn To Talc Settlement Proposal To Smooth Path To Kenvue Consumer Spinoff

Firm proposes larger funding agreement to settle North American talc claims, apparently pivoting from appealing to Supreme Court a January circuit court decision upholding bankruptcy court ruling that its LTL subsidiary isn’t “financially distressed” enough to file for Chapter protection.

J&J’s Talc Subsidiary Not ‘Financially Distressed’ Enough For Bankruptcy – Third Circuit

The J&J company holding the firm’s liabilities relating to talc litigation, which declared bankruptcy in 2021 shortly after its formation, had its Chapter 11 petition denied by the Third Circuit on 30 January. Attorneys weigh in on the implications for J&J and wider industry.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts